Overview

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Status:
RECRUITING

Trial end date:
2036-05-22

Target enrollment:

Participant gender:

Summary

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

abiraterone
Androgen Antagonists
AZD5305
Prednisolone
Prednisone